Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Victor Gurewich

Title
Institution
Department
Address
Phone
Fax

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. van der Ende NAM, Roozenbeek B, Smagge LEM, Luijten SPR, Aerden LAM, Kraayeveld P, van den Wijngaard IR, Lycklama À Nijeholt GJ, den Hertog HM, Flach HZ, Wallace AC, Gurewich V, Del Zoppo GJ, Meurer WJ, Lingsma HF, van der Lugt A, Dippel DWJ. Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial. Trials. 2022 Aug 09; 23(1):641. PMID: 35945566; PMCID: PMC9361639.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  2. Gurewich V. Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown. Cardiovasc Drugs Ther. 2019 12; 33(6):749-753. PMID: 31897763.
    Citations: 1     Fields:    Translation:HumansAnimals
  3. Gurewich V, Pannell R. A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects: comment. J Thromb Haemost. 2017 10; 15(10):2080-2081. PMID: 28799246.
    Citations: 1     Fields:    Translation:Humans
  4. Pannell R, Li S, Gurewich V. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination. J Thromb Thrombolysis. 2017 Aug; 44(2):210-215. PMID: 28600623.
    Citations: 2     Fields:    Translation:Humans
  5. Gurewich V. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII: comment. J Thromb Haemost. 2017 01; 15(1):204-205. PMID: 27749008.
    Citations:    Fields:    Translation:Humans
  6. Gurewich V. Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved. J Am Coll Cardiol. 2016 11 08; 68(19):2099-2106. PMID: 27810050.
    Citations: 10     Fields:    Translation:Humans
  7. Gurewich V, Pannell R. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor: comment. J Thromb Haemost. 2016 09; 14(9):1899-900. PMID: 27343843.
    Citations: 1     Fields:    Translation:Humans
  8. Gurewich V. Thrombolysis: A Critical First-Line Therapy with an Unfulfilled Potential. Am J Med. 2016 06; 129(6):573-5. PMID: 26714208.
    Citations: 13     Fields:    Translation:Humans
  9. Gurewich V. Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement. J Thromb Thrombolysis. 2015 Nov; 40(4):480-7. PMID: 25894475; PMCID: PMC4584119.
    Citations: 1     Fields:    Translation:Humans
  10. Pannell R, Li S, Gurewich V. Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK. PLoS One. 2015; 10(3):e0122018. PMID: 25811605; PMCID: PMC4374801.
    Citations: 3     Fields:    Translation:Humans
  11. El-Ayoubi F, Amiral J, Pascaud J, Charrin S, Tassel B, Uzan G, Gurewich V. A fibrin antibody binding to fibronectin induces potent inhibition of angiogenesis. Thromb Haemost. 2015 Jan; 113(1):143-53. PMID: 25252851.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  12. Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke. PLoS One. 2011; 6(7):e21999. PMID: 21779364.
    Citations: 8     Fields:    Translation:HumansAnimals
  13. Gurewich V, Pannell R. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis. Thromb Haemost. 2009 Aug; 102(2):279-86. PMID: 19652878.
    Citations: 4     Fields:    Translation:HumansAnimals
  14. Gurewich V. Primary percutaneous coronary intervention. N Engl J Med. 2008 Jan 24; 358(4):431-2; author reply 432-3. PMID: 18219753.
    Citations:    Fields:    Translation:Humans
  15. Lacroix R, Sabatier F, Mialhe A, Basire A, Pannell R, Borghi H, Robert S, Lamy E, Plawinski L, Camoin-Jau L, Gurewich V, Angles-Cano E, Dignat-George F. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood. 2007 Oct 01; 110(7):2432-9. PMID: 17606760; PMCID: PMC2495018.
    Citations: 75     Fields:    Translation:HumansCells
  16. Pannell R, Kung W, Gurewich V. C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis. J Thromb Haemost. 2007 May; 5(5):1047-54. PMID: 17459007.
    Citations: 4     Fields:    Translation:Humans
  17. Gurewich V, Pannell R, Simmons-Byrd A, Sarmientos P, Liu JN, Badylak SF. Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator. J Thromb Haemost. 2006 Jul; 4(7):1559-65. PMID: 16839354.
    Citations: 8     Fields:    Translation:Animals
  18. Basire A, Sabatier F, Ravet S, Lamy E, Mialhe A, Zabouo G, Paul P, Gurewich V, Sampol J, Dignat-George F. High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors. Thromb Haemost. 2006 Apr; 95(4):678-88. PMID: 16601839.
    Citations: 19     Fields:    Translation:HumansCells
  19. Gurewich V. Health care in the 21st century. N Engl J Med. 2005 May 05; 352(18):1927-8. PMID: 15872211.
    Citations:    Fields:    Translation:Humans
  20. Gurewich V. Ximelagatran--promises and concerns. JAMA. 2005 Feb 09; 293(6):736-9. PMID: 15701916.
    Citations: 9     Fields:    Translation:Humans
  21. Camoin-Jau L, Pannell R, Anfosso F, Bardin N, Sabatier F, Sampol J, Gurewich V, Dignat-George F. Platelet associated u-PA up-regulates u-PA synthesis by endothelial cells. Thromb Haemost. 2002 Sep; 88(3):517-23. PMID: 12353084.
    Citations: 1     Fields:    Translation:HumansCells
  22. Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P, Liu JN. The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29; 1596(2):182-92. PMID: 12007600.
    Citations: 25     Fields:    Translation:Cells
  23. Liu JN, Liu JX, Liu Bf BF, Sun Z, Zuo JL, Zhang Px PX, Zhang J, Chen Yh YH, Gurewich V. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis. Circ Res. 2002 Apr 19; 90(7):757-63. PMID: 11964367.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  24. Sun Z, Zhang PX, Wang P, Gurewich V, Shen HY, Liu JN. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation. Thromb Res. 2002 Apr 15; 106(2):105-11. PMID: 12182908.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  25. Li C, Zhang J, Jiang Y, Gurewich V, Chen Y, Liu JN. Urokinase-type plasminogen activator up-regulates its own expression by endothelial cells and monocytes via the u-PAR pathway. Thromb Res. 2001 Aug 01; 103(3):221-32. PMID: 11672584.
    Citations: 8     Fields:    Translation:HumansCells
  26. Wang P, Zhang J, Sun Z, Chen Y, Gurewich V, Liu JN. Catalytic and fibrinolytic properties of recombinant urokinase plasminogen activator from E. coli, mammalian, and yeast cells. Thromb Res. 2000 Dec 01; 100(5):461-7. PMID: 11150590.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  27. Gurewich V. Fibrinolysis: an unfinished agenda. Blood Coagul Fibrinolysis. 2000 Jul; 11(5):401-8. PMID: 10937799.
    Citations: 3     Fields:    Translation:Humans
  28. Camoin L, Pannell R, Anfosso F, Lefevre JP, Sampol J, Gurewich V, Dignat-George F. Evidence for the expression of urokinase-type plasminogen activator by human venous endothelial cells in vivo. Thromb Haemost. 1998 Dec; 80(6):961-7. PMID: 9869168.
    Citations:    Fields:    Translation:HumansCells
  29. Gurewich V. Managed care ethics. Ann Intern Med. 1998 Oct 15; 129(8):672-3; author reply 674. PMID: 9786828.
    Citations:    Fields:    Translation:Humans
  30. Gurewich V. A comparison of recombinant urokinase with vascular surgery for acute arterial occlusion of the legs. N Engl J Med. 1998 Aug 20; 339(8):564-5. PMID: 9714627.
    Citations:    Fields:    Translation:Humans
  31. Gurewich V. Truth or consequences. N Engl J Med. 1998 Aug 06; 339(6):410-1; author reply 411-2. PMID: 9696666.
    Citations:    Fields:    Translation:Humans
  32. Gurewich V, Liu JN. Intra-arterial pro-urokinase in ischemic stroke. Stroke. 1998 Jun; 29(6):1255-6. PMID: 9626302.
    Citations: 2     Fields:    Translation:Humans
  33. Liu JN, Kung W, Harpel PC, Gurewich V. Demonstration of covalent binding of lipoprotein(a) [Lp(a)] to fibrin and endothelial cells. Biochemistry. 1998 Mar 17; 37(11):3949-54. PMID: 9521716.
    Citations: 1     Fields:    Translation:HumansCells
  34. Sun Z, Liu BF, Chen Y, Gurewich V, Zhu D, Liu JN. Analysis of the forces which stabilize the active conformation of urokinase-type plasminogen activator. Biochemistry. 1998 Mar 03; 37(9):2935-40. PMID: 9485445.
    Citations:    Fields:    Translation:Cells
  35. Tang W, Sun ZY, Pannell R, Gurewich V, Liu JN. An efficient system for production of recombinant urokinase-type plasminogen activator. Protein Expr Purif. 1997 Dec; 11(3):279-83. PMID: 9425632.
    Citations: 2     Fields:    Translation:HumansCells
  36. Lenich C, Liu JN, Gurewich V. Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator. Blood. 1997 Nov 01; 90(9):3579-86. PMID: 9345041.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  37. Sun Z, Jiang Y, Ma Z, Wu H, Liu BF, Xue Y, Tang W, Chen Y, Li C, Zhu D, Gurewich V, Liu JN, Zhong M, Xu Y. Identification of a flexible loop region (297-313) of urokinase-type plasminogen activator, which helps determine its catalytic activity. J Biol Chem. 1997 Sep 19; 272(38):23818-23. PMID: 9295329.
    Citations: 5     Fields:    Translation:Cells
  38. Liu JN, Tang W, Sun ZY, Kung W, Pannell R, Sarmientos P, Gurewich V. A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. Biochemistry. 1996 Nov 12; 35(45):14070-6. PMID: 8916892.
    Citations: 8     Fields:    Translation:HumansCells
  39. Li C, Gurewich V, Liu JN. Urokinase-type plasminogen activator-induced monocyte adhesion is modulated by kininogen, kallikrein, factor XII, and plasminogen. Exp Cell Res. 1996 Aug 01; 226(2):239-42. PMID: 8806427.
    Citations: 1     Fields:    Translation:HumansCells
  40. Tang W, Liu JN, Gurewich V. Preparation of single-stranded phagemid DNA without chromosomal DNA contamination. Biotechniques. 1996 Jul; 21(1):53-4. PMID: 8816234.
    Citations: 1     Fields:    Translation:Cells
  41. Jick H, Derby LE, Gurewich V, Vasilakis C. The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy. 1996 May-Jun; 16(3):321-6. PMID: 8726591.
    Citations: 12     Fields:    Translation:Humans
  42. Jiang Y, Pannell R, Liu JN, Gurewich V. Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes. Blood. 1996 Apr 01; 87(7):2775-81. PMID: 8639894.
    Citations: 7     Fields:    Translation:HumansCells
  43. Gurewich V, Muller J. Is coronary thrombolysis associated with side effects that significantly compromise clinical benefits? Am J Cardiol. 1996 Apr 01; 77(9):756-8. PMID: 8651129.
    Citations:    Fields:    Translation:Humans
  44. Li C, Liu JN, Gurewich V. Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction. J Biol Chem. 1995 Dec 22; 270(51):30282-5. PMID: 8530448.
    Citations: 2     Fields:    Translation:HumansCells
  45. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995 Dec 16; 346(8990):1589-93. PMID: 7500750.
    Citations: 94     Fields:    Translation:Humans
  46. Lenich C, Pannell R, Gurewich V. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb Haemost. 1995 Aug; 74(2):698-703. PMID: 8585009.
    Citations: 2     Fields:    Translation:HumansCells
  47. Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, Byrnes C, Muller JE, Gurewich V. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial. J Am Coll Cardiol. 1995 Aug; 26(2):374-9. PMID: 7608437.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  48. Liu JN, Gurewich V. Inactivation of the intrinsic activity of pro-urokinase by diisopropyl fluorophosphate is reversible. J Biol Chem. 1995 Apr 14; 270(15):8408-10. PMID: 7721734.
    Citations:    Fields:    Translation:Cells
  49. Moia M, Mannucci PM, Pini M, Prandoni P, Gurewich V. A pilot study of pro-urokinase in the treatment of deep vein thrombosis. Thromb Haemost. 1994 Sep; 72(3):430-3. PMID: 7531876.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  50. Gurewich V, Mittleman M. Lipoprotein(a) in coronary heart disease. Is it a risk factor after all? JAMA. 1994 Apr 06; 271(13):1025-6. PMID: 8139062.
    Citations: 3     Fields:    Translation:Humans
  51. Liu J, Harpel PC, Gurewich V. Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin. Biochemistry. 1994 Mar 08; 33(9):2554-60. PMID: 8117716.
    Citations: 2     Fields:    Translation:HumansCells
  52. Loza JP, Gurewich V, Johnstone M, Pannell R. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost. 1994 Mar; 71(3):347-52. PMID: 8029800.
    Citations: 5     Fields:    Translation:HumansCells
  53. Gurewich V. Thrombolytic agents. N Engl J Med. 1994 Jan 27; 330(4):291. PMID: 8272100.
    Citations:    Fields:    Translation:Humans
  54. Liu JN, Harpel PC, Pannell R, Gurewich V. Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator. Biochemistry. 1993 Sep 21; 32(37):9694-700. PMID: 8373773.
    Citations: 2     Fields:    Translation:Cells
  55. Liu J, Gurewich V. Substrate inhibition of fibrin-dependent plasminogen activation by tissue-type plasminogen activator. J Biol Chem. 1993 Jun 15; 268(17):12257-9. PMID: 8509362.
    Citations:    Fields:    Translation:HumansCells
  56. Gurewich V. Coronary rethrombosis after successful thrombolysis. Circulation. 1993 May; 87(5):1759-61. PMID: 8491032.
    Citations: 1     Fields:    Translation:Humans
  57. Gurewich V, Johnstone M, Loza JP, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett. 1993 Mar 08; 318(3):317-21. PMID: 8440390.
    Citations: 1     Fields:    Translation:HumansCells
  58. Liu JN, Gurewich V. The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator. Blood. 1993 Feb 15; 81(4):980-7. PMID: 8428004.
    Citations: 1     Fields:    Translation:AnimalsCells
  59. Gurewich V, Liu JN, Pannell R. The intrinsic lysis concept. Ann N Y Acad Sci. 1992 Dec 04; 667:224-32. PMID: 1309040.
    Citations: 1     Fields:    Translation:HumansAnimals
  60. Lenich C, Pannell R, Henkin J, Gurewich V. The influence of glycosylation on the catalytic and fibrinolytic properties of pro-urokinase. Thromb Haemost. 1992 Nov 10; 68(5):539-44. PMID: 1455401.
    Citations: 3     Fields:    Translation:HumansCells
  61. Liu JN, Pannell R, Gurewich V. A transitional state of pro-urokinase that has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem. 1992 Aug 05; 267(22):15289-92. PMID: 1639775.
    Citations: 4     Fields:    Translation:HumansCells
  62. Liu JN, Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. Biochemistry. 1992 Jul 14; 31(27):6311-7. PMID: 1385727.
    Citations: 12     Fields:    Translation:HumansCells
  63. Kirshenbaum JM, Bahr RD, Flaherty JT, Gurewich V, Levine HJ, Loscalzo J, Schumacher RR, Topol EJ, Wahr DW, Braunwald E. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group. Am J Cardiol. 1991 Dec 15; 68(17):1564-9. PMID: 1746455.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  64. Liu JN, Gurewich V. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest. 1991 Dec; 88(6):2012-7. PMID: 1836471; PMCID: PMC295789.
    Citations: 9     Fields:    
  65. Lenich C, Pannell R, Gurewich V. The effect of the carboxy-terminal lysine of urokinase on the catalysis of plasminogen activation. Thromb Res. 1991 Oct 01; 64(1):69-80. PMID: 1776140.
    Citations:    Fields:    Translation:HumansCells
  66. Pannell R, Angles-Cano E, Gurewich V. The pH dependence of the binding of pro-urokinase to fibrin/celite. Thromb Haemost. 1990 Dec 28; 64(4):556-8. PMID: 2128139.
    Citations:    Fields:    Translation:HumansCells
  67. Silverstein RL, Nachman RL, Pannell R, Gurewich V, Harpel PC. Thrombospondin forms complexes with single-chain and two-chain forms of urokinase. J Biol Chem. 1990 Jul 05; 265(19):11289-94. PMID: 2141608.
    Citations: 9     Fields:    Translation:HumansCells
  68. Bode C, Schuler G, Nordt T, Schönermark S, Baumann H, Richardt G, Dietz R, Gurewich V, Kübler W. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction. Circulation. 1990 Mar; 81(3):907-13. PMID: 2106403.
    Citations: 3     Fields:    Translation:Humans
  69. Gurewich V. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase. Semin Thromb Hemost. 1989 Apr; 15(2):123-8. PMID: 2501871.
    Citations: 2     Fields:    Translation:Humans
  70. Gurewich V, Pannell R, Broeze RJ, Mao J. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158). J Clin Invest. 1988 Dec; 82(6):1956-62. PMID: 2974047; PMCID: PMC442777.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  71. Dwivedi C, Pannell R, Gurewich V. Fibrin activatable urokinase (FA-UK): a latent form of UK found in urine related to a complex with an inhibitor/fibrin-interacting cofactor. Thromb Res. 1988 Jul 15; 51(2):197-208. PMID: 3055414.
    Citations:    Fields:    Translation:HumansCells
  72. Pannell R, Black J, Gurewich V. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest. 1988 Mar; 81(3):853-9. PMID: 2963831; PMCID: PMC442536.
    Citations: 17     Fields:    Translation:Humans
  73. Kasper W, Meinertz T, Hohnloser S, Engler H, Hasler C, Rössler W, Wolf H, Welzel D, Just H, Gurewich V. Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase. Klin Wochenschr. 1988; 66 Suppl 12:109-14. PMID: 3126340.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  74. Gurewich V. Pro-urokinase: physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action. Semin Thromb Hemost. 1988 Jan; 14(1):110-5. PMID: 3127884.
    Citations: 2     Fields:    Translation:HumansAnimals
  75. Gurewich V. Activation of fibrin-bound plasminogen by pro-urokinase and its complementariness with that by tissue plasminogen activator. Enzyme. 1988; 40(2-3):97-108. PMID: 2971533.
    Citations: 1     Fields:    Translation:HumansCells
  76. Gurewich V. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator. J Am Coll Cardiol. 1987 Nov; 10(5 Suppl B):16B-21B. PMID: 3117859.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  77. Gurewich V, Pannell R. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thromb Haemost. 1987 Jun 03; 57(3):372-3. PMID: 3116707.
    Citations: 5     Fields:    Translation:Humans
  78. Gurewich V, Pannell R. Fibrin binding and zymogenic properties of single-chain urokinase (pro-urokinase). Semin Thromb Hemost. 1987 Apr; 13(2):146-51. PMID: 3114882.
    Citations:    Fields:    Translation:HumansCells
  79. Gurewich V, Pannell R. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments. Blood. 1987 Mar; 69(3):769-72. PMID: 2949785.
    Citations: 9     Fields:    Translation:Cells
  80. Lipinska I, Gurewich V, Meriam CM, Kosowsky BD, Ramaswamy K, Philbin E, Losordo D. Lipids, lipoproteins, fibrinogen and fibrinolytic activity in angiographically assessed coronary heart disease. Artery. 1987; 15(1):44-60. PMID: 3435252.
    Citations:    Fields:    Translation:Humans
  81. Pannell R, Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood. 1987 Jan; 69(1):22-6. PMID: 3790724.
    Citations: 18     Fields:    Translation:HumansCells
  82. Gurewich V, Pannell R. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. Thromb Res. 1986 Oct 15; 44(2):217-28. PMID: 3097872.
    Citations: 4     Fields:    Translation:HumansCells
  83. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood. 1986 May; 67(5):1215-23. PMID: 3083889.
    Citations: 24     Fields:    Translation:HumansCells
  84. Gurewich V, Pannell R. Thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1985 Sep 26; 313(13):825. PMID: 4033712.
    Citations:    Fields:    Translation:Humans
  85. Gurewich V, Pannell R. Biological properties of recombinant and of natural pro-urokinase. Thromb Haemost. 1985 Aug 30; 54(2):558-9. PMID: 3936220.
    Citations:    Fields:    Translation:HumansAnimals
  86. Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest. 1984 Jun; 73(6):1731-9. PMID: 6725557; PMCID: PMC437085.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  87. Louie S, Gurewich V. The antithrombotic effect of aspirin and dipyridamole in relation to prostaglandin synthesis. Thromb Res. 1983 May 15; 30(4):323-35. PMID: 6351340.
    Citations: 2     Fields:    Translation:Animals
  88. Gurewich V. Exercise-induced fibrinolysis--fact not fiction. Thromb Haemost. 1983 Apr 28; 49(2):149. PMID: 6868010.
    Citations:    Fields:    Translation:Humans
  89. Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys. 1983 Jan; 220(1):31-8. PMID: 6338833.
    Citations: 11     Fields:    Translation:Humans
  90. Gurewich V, Lipinska I, Lipinski B. High-density lipoproteins and atherosclerosis. N Engl J Med. 1982 Nov 11; 307(20):1274-5. PMID: 7133062.
    Citations:    Fields:    Translation:Humans
  91. Lipinska I, Gurewich V. The value of measuring percent high-density lipoprotein in assessing risk of cardiovascular disease. Arch Intern Med. 1982 Mar; 142(3):469-72. PMID: 7065784.
    Citations: 2     Fields:    Translation:HumansCells
  92. Gurewich V, Lipinska I, Gordon EE, Pulini M. Lower molecular weight fibrinogen and non-clottable fibrinogen derivatives in diabetes mellitus. Thromb Res. 1981 Jun 1-25; 22(5-6):535-41. PMID: 7302905.
    Citations: 2     Fields:    Translation:Humans
  93. Pandian NG, Kosowsky BD, Gurewich V. Transfemoral temporary pacing and deep vein thrombosis. Am Heart J. 1980 Dec; 100(6 Pt 1):847-51. PMID: 7446387.
    Citations: 3     Fields:    Translation:Humans
  94. Foti ME, Gurewich V. Fibrin degradation products and impedance plethysmography. Measurements in the diagnosis of acute deep vein thrombosis. Arch Intern Med. 1980 Jul; 140(7):903-6. PMID: 7387297.
    Citations: 1     Fields:    Translation:Humans
  95. Lipinski B, Gurewich V. Alpha 2-plasmin inhibitor deficiency. Lancet. 1979 Feb 10; 1(8111):329. PMID: 84984.
    Citations:    Fields:    Translation:Humans
  96. Gurewich V, Nunn T, Lipinski B. Activation of intrinsic or extrinsic blood coagulation in experimental venous thrombosis and disseminated intravascular coagulation: pathogenetic differences. Thromb Res. 1979; 14(6):931-40. PMID: 473128.
    Citations: 3     Fields:    Translation:HumansAnimals
  97. Roncucci R, De Hertogh R, Dormandy JA, Doumont J, Gurewich V, Lambelin G, Lansen J, Rottiers R, Souridis E, Van Stalle F, Versee L. Effects of long-term treatment with suloctidil on blood viscosity, erythrocyte deformability and total fibrinogen plasma levels in diabetic patients. Arzneimittelforschung. 1979; 29(4):682-4. PMID: 582768.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  98. Malt RA, Dalton JC, Johnson RE, Gurewich V. Side-to-side portacaval shunt versus nonsurgical treatment of Budd-Chiari syndrome. Am J Surg. 1978 Sep; 136(3):387-9. PMID: 707712.
    Citations: 6     Fields:    Translation:Humans
  99. Gurewich V, Nunn T, Kuriakose TT, Hume M. Hemostatic effects of uniform, low-dose subcutaneous heparin in surgical patients. Arch Intern Med. 1978 Jan; 138(1):41-4. PMID: 619830.
    Citations: 2     Fields:    Translation:Humans
  100. Gurewich V. Thrombolytic treatment of venous thromboembolism. Vasc Surg. 1977 Nov-Dec; 11(6):341-2. PMID: 616147.
    Citations: 1     Fields:    Translation:Humans
  101. Deykin D, Gurewich V, Harker L, Hirsch J. Treating thromboembolic disease. Geriatrics. 1977 Oct; 32(10):119-21, 125-8. PMID: 302814.
    Citations:    Fields:    Translation:Humans
  102. Lipinski B, Lipinska I, Nowak A, Gurewich V. Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease. J Lab Clin Med. 1977 Jul; 90(1):187-94. PMID: 406338.
    Citations: 3     Fields:    Translation:Humans
  103. Gurewich V, Lipinski B. Case report: low-dose intravenous heparin in the treatment of disseminated intravascular coagulation. Am J Med Sci. 1977 Jul-Aug; 274(1):83-6. PMID: 911396.
    Citations:    Fields:    Translation:Humans
  104. Lipinski B, Gurewich V, Lipinska I. Thrombin time prolongation in cirrhosis in relation to enhanced fibrinogen degradation. Thromb Res. 1977 Jan; 10(1):185-7. PMID: 850901.
    Citations:    Fields:    Translation:Humans
  105. Gurewich V, Lipinski B, Hyde E. The effect of the fibrinogen concentration and the leukocyte count on intravascular fibrin deposition from soluble fibrin monomer complexes. Thromb Haemost. 1976 Dec 31; 36(3):605-14. PMID: 1037154.
    Citations: 7     Fields:    Translation:Animals
  106. Lipinski B, Gurewich V, Hyde E. Thrombin elaboration in endotoxin-induced intravascular fibrin deposition. A leukocyte dependent process distinct from systemic hypercoagulability. Thromb Haemost. 1976 Dec 31; 36(3):615-22. PMID: 1037155.
    Citations:    Fields:    Translation:AnimalsCells
  107. Lipinska I, Lipinski B, Gurewich V, Hoffmann KD. Fibrinogen heterogeneity in cancer, in occlusive vascular disease, and after surgical procedures. Am J Clin Pathol. 1976 Dec; 66(6):958-66. PMID: 998569.
    Citations: 4     Fields:    Translation:Humans
  108. Gurewich V, Lipinski B. Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole. Thromb Res. 1976 Aug; 9(2):101-8. PMID: 968808.
    Citations: 2     Fields:    Translation:AnimalsCells
  109. Lipinski B, Gurewich V. The effect of leukopenia versus thrombocytopenia on endotoxin induced intravascular coagulation. Thromb Res. 1976 Mar; 8(3):403-11. PMID: 1265711.
    Citations: 1     Fields:    Translation:AnimalsCells
  110. Gurewich V, Lipinski B. Semiquantitative determination of soluble fibrin monomer complexes by chromatography and serial-dilution protamine sulfate test. Am J Clin Pathol. 1976 Mar; 65(3):397-401. PMID: 769532.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  111. Gurewich V, Lipinski B, Wetmore R. A study of the large heparin requirements in the generalized Shwartzman reaction. Blood. 1976 Feb; 47(2):297-304. PMID: 1244924.
    Citations:    Fields:    Translation:Animals
  112. Lipinski B, Gurewich V. Letter: The degradation of soluble versus insoluble fibrin in vivo. Thromb Res. 1976 Jan; 8(1):119-20. PMID: 129882.
    Citations: 1     Fields:    
  113. Gurewich V. Guidelines for the management of anticoagulant therapy. Semin Thromb Hemost. 1976 Jan; 2(3):176-96. PMID: 798275.
    Citations: 3     Fields:    Translation:Humans
  114. Gurewich V, Lipinski B. Proceedings: The role of platelets and leukocytes in endotoxin-induced disseminated intravascular coagulation (DIC). Thromb Diath Haemorrh. 1975 Nov 15; 34(2):603. PMID: 1198527.
    Citations:    Fields:    Translation:AnimalsCells
  115. Gurewich V, Hyde E, Lipinski B. The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs. Blood. 1975 Oct; 46(4):555-65. PMID: 126095.
    Citations: 5     Fields:    Translation:Humans
  116. Lipinski B, Gurewich V, Hyde E. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK). Thromb Diath Haemorrh. 1975 Sep 30; 34(1):351. PMID: 1188799.
    Citations:    Fields:    Translation:Humans
  117. Gurewich V, Lipinski B, Wetmore R. Inhibition of intravascular fibrin deposition by dipyridamole in experimental animals. Blood. 1975 Apr; 45(4):569-75. PMID: 1090312.
    Citations: 2     Fields:    Translation:AnimalsCells
  118. Hyde E, Wetmore R, Gurewich V. Letter: Inhibitor to blood coagulation elicited by thrombin. Am J Clin Pathol. 1975 Apr; 63(4):584. PMID: 1119452.
    Citations:    Fields:    Translation:Animals
  119. Gurewich V, Nowak A, Lipinska I, Lipinska B. The resistance of soluble derivatives of fibrinogen and the sensitivity of its insouble forms to fibrinolytic degradation in blood. Thromb Diath Haemorrh. 1974 Dec 31; 32(2-3):582-91. PMID: 4454050.
    Citations: 1     Fields:    Translation:Humans
  120. Gurewich V, Wetmore R, Nowak A, Lipinski B. The fate of soluble fibrin monomer in relation to intravascular fibrin formation and degradation in rabbits. Blood. 1974 Nov; 44(5):723-33. PMID: 4420440.
    Citations: 1     Fields:    Translation:Animals
  121. Gurewich V, Lipinska I, Lipinski B. Excercise-induced fibrinolytic activity and its effect on the degradation of fibrinogen, fibrin and fibrin-like precipitates. Thromb Res. 1974 Nov; 5(5):647-56. PMID: 4445987.
    Citations: 1     Fields:    Translation:Humans
  122. Lipinska I, Lipinski B, Gurewich V. Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major fibrinogen components. J Lab Clin Med. 1974 Oct; 84(4):509-16. PMID: 4413464.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  123. Gurewich V, Lipinski B. Letter: Heparin dosage and clotting time. Ann Intern Med. 1974 Oct; 81(4):567-8. PMID: 4414251.
    Citations:    Fields:    Translation:Humans
  124. Lipinski B, Nowak A, Gurewich V. The organ distribution of 125I-fibrin in the generalized Shwartzman reaction and its relation to leucocytes. Br J Haematol. 1974 Oct; 28(2):221-31. PMID: 4433480.
    Citations: 3     Fields:    Translation:AnimalsCells
  125. Gurewich V. Letter: Causes of a negative ethanol gelation test in diffuse intravascular coagulation. Thromb Diath Haemorrh. 1974 Sep 30; 32(1):243-4. PMID: 4454044.
    Citations: 1     Fields:    
  126. Lipinski B, Gurewich V, Nowak A, Wetmore R. The effect of heparin and dipyridamole on the deposition of fibrin-like material in rabbits infused with soluble fibrin monomer or fibrinogen. Thromb Res. 1974 Sep; 5(3):343-58. PMID: 4439374.
    Citations: 3     Fields:    Translation:Animals
  127. Lipinski B, Lipinska I, Gurewich V. Letter: The fibrinogenolytic pathway of fibrinogen catabolism: additional comments. Thromb Res. 1974 Jun; 4(6):891-4. PMID: 4844066.
    Citations: 1     Fields:    Translation:Humans
  128. Nowak A, Gurewich V. Thrombolysis with streptokinase in rabbits. Dose response, fibrin-clot specificity and laboratory evaluation of fibrinolytic effect. Thromb Diath Haemorrh. 1974 May 15; 31(2):265-72. PMID: 4855199.
    Citations: 2     Fields:    Translation:Animals
  129. Gurewich V. Letter: Heparin, aspirin and Lee-White clotting time. Chest. 1974 Apr; 65(4):475. PMID: 4819260.
    Citations:    Fields:    Translation:HumansCells
  130. Hyde E, Wetmore R, Gurewich V. Isolation and characterization of an in vivo thrombin-induced anticoagulant activity. Scand J Haematol. 1974; 13(2):121-8. PMID: 4417990.
    Citations:    Fields:    Translation:AnimalsCells
  131. Wetmore R, Gurewich V. The role of fibrin monomer and an in vivo thrombin-induced-anticoagulant in experimental venous thrombosis. Scand J Haematol. 1974; 12(3):204-12. PMID: 4831824.
    Citations: 1     Fields:    Translation:AnimalsCells
  132. Hyde E, Joyce D, Gurewich V, Flute PT, Barrera S. Intravascular coagulation during pregnancy and the puerperium. J Obstet Gynaecol Br Commonw. 1973 Dec; 80(12):1059-66. PMID: 4761380.
    Citations: 3     Fields:    Translation:HumansCells
  133. Gurewich V. Letter: Haemostasis, fibrinolysis, and deep-vein thrombosis. Lancet. 1973 Nov 10; 2(7837):1083-4. PMID: 4127334.
    Citations:    Fields:    Translation:Humans
  134. Gurewich V, Hume M, Patrick M. The laboratory diagnosis of venous thromboembolic disease by measurement of fibrinogen-fibrin degradation products and fibrin monomer. Chest. 1973 Nov; 64(5):585-90. PMID: 4750329.
    Citations: 2     Fields:    Translation:HumansCells
  135. Gurewich V. Letter: Ethanol gelation and protamine sulfate. Comparison and critique. Thromb Diath Haemorrh. 1973 Jun 28; 29(3):733-4. PMID: 4761839.
    Citations:    Fields:    
  136. Gurewich V. Pulmonary thromboembolism. Cardiovasc Clin. 1973; 5(1):273-85. PMID: 4589964.
    Citations:    Fields:    Translation:HumansAnimals
  137. Halpin DS, Jefferiss CD, Ling RS, Hume M, Gurewich V, Negus D, Evans DS. Peripheral venous scanning with 125 I-tagged fibrinogen. Lancet. 1972 Apr 15; 1(7755):845-6. PMID: 4111602.
    Citations:    Fields:    Translation:Humans
  138. Gurewich V, Hutchinson E. Detection of intravascular coagulation by a serial-dilution protamine sulfate test. Ann Intern Med. 1971 Dec; 75(6):895-902. PMID: 5134899.
    Citations: 10     Fields:    Translation:HumansCells
  139. Roberts VC, Sabri S, Pietroni MC, Gurewich V, Cotton LT. Passive flexion and femoral vein flow: a study using a motorized foot mover. Br Med J. 1971 Jul 10; 3(5766):78-81. PMID: 5090824; PMCID: PMC1800143.
    Citations: 7     Fields:    Translation:Humans
  140. Rosoff CB, Salzman EW, Gurewich V. Reduction of platelet serotonin and the response to pulmonary emboli. Surgery. 1971 Jul; 70(1):12-9. PMID: 4326431.
    Citations: 6     Fields:    Translation:AnimalsCells
  141. Niewiarowski S, Gurewich V. Laboratory identification of intravascular coagulation. The serial dilution protamine sulfate test for the detection of fibrin monomer and fibrin degradation products. J Lab Clin Med. 1971 Apr; 77(4):665-76. PMID: 4928905.
    Citations: 27     Fields:    Translation:HumansAnimalsCells
  142. Hume M, Gurewich V, Thomas DP, Dealy JB. Streptokinase for chronic arterial occlusive disease. Arch Surg. 1970 Dec; 101(6):653-7. PMID: 5489287.
    Citations: 3     Fields:    Translation:Humans
  143. Gurewich V, Thomas DP. Streptokinase in acute pulmonary embolism. J Thorac Cardiovasc Surg. 1970 May; 59(5):655-61. PMID: 5439686.
    Citations:    Fields:    Translation:AnimalsCells
  144. Hawiger J, Niewiarowski S, Gurewich V, Thomas DP. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. J Lab Clin Med. 1970 Jan; 75(1):93-108. PMID: 4243578.
    Citations: 46     Fields:    Translation:HumansAnimalsCells
  145. Gurewich V, Cohen ML, Thomas DP. Humoral factors in massive pulmonary embolism: an experimental study. Am Heart J. 1968 Dec; 76(6):784-94. PMID: 5721836.
    Citations: 13     Fields:    Translation:AnimalsCells
  146. Thomas DP, Gurewich V, Stuart RK. Epinephrine potentiation of platelet aggregation: its effect on death from experimental pulmonaryeembolism. J Lab Clin Med. 1968 Jun; 71(6):955-63. PMID: 5654778.
    Citations:    Fields:    Translation:AnimalsCells
  147. Gurewich V, Thomas DP, Stuart RK. Some guidelines for heparin therapy of venous thromboembolic disease. JAMA. 1967 Jan 09; 199(2):116-8. PMID: 5333700.
    Citations: 8     Fields:    Translation:Humans
  148. Gurewich V, Thomas DP, Rabinov KR. Pulmonary embolism after ligation of the inferior vena cava. N Engl J Med. 1966 Jun 16; 274(24):1350-4. PMID: 5934963.
    Citations: 10     Fields:    Translation:Humans
  149. Thomas DP, Gurewich V, Ashford TP. Platelet adherence to thromboemboli in relation to the pathogenesis and treatment of pulmonary embolism. N Engl J Med. 1966 Apr 28; 274(17):953-6. PMID: 5908890.
    Citations: 13     Fields:    Translation:AnimalsCells
  150. Gurewich V, Thomas DP. Pathogenesis of venous thrombosis in relation to its prevention by dextran and heparin. J Lab Clin Med. 1965 Oct; 66(4):604-12. PMID: 5843088.
    Citations: 7     Fields:    Translation:Animals
  151. REAM VJ, DEYKIN D, GUREWICH V, WESSLER S. THE AGGREGATION OF HUMAN PLATELETS BY BACTERIAL ENDOTOXIN. J Lab Clin Med. 1965 Aug; 66:245-52. PMID: 14322070.
    Citations: 13     Fields:    Translation:HumansCells
  152. GUREWICH V, THOMAS D, STEIN M, WESSLER S. Bronchoconstriction in the presence of pulmonary embolism. Circulation. 1963 Mar; 27:339-45. PMID: 13951344.
    Citations: 13     Fields:    Translation:Humans
  153. GUREWICH V, SASAHARA AA, QUINN JS, PEFFER CJ, LITTMANN D. Aortic pressures during closed-chest cardiac massage. Circulation. 1961 Apr; 23:593-5. PMID: 13709859.
    Citations: 4     Fields:    
  154. GUREWICH V, THOMAS D. Massive intraperitoneal hemorrhage from a ruptured corpus luteum: a rare complication of long-term anticoagulant therapy. N Engl J Med. 1960 Nov 03; 263:909-10. PMID: 13709860.
    Citations: 2     Fields:    Translation:Humans
  155. WESSLER S, MING SC, GUREWICH V, FREIMAN DG. A critical evaluation of thromboangitis obliterans. The case against Buerger's disease. N Engl J Med. 1960 Jun 09; 262:1149-60. PMID: 13844117.
    Citations: 13     Fields:    Translation:Humans
  156. GUREWICH V, THOMAS MA. Idiopathic pulmonary hemorrhage in pregnancy. Report of a case suggesting early pulmonary hemosiderosis with clinical recovery after steroid therapy. N Engl J Med. 1959 Dec 03; 261:1154-9. PMID: 13830349.
    Citations: 3     Fields:    Translation:Humans
  157. ALEXANDER B, MEYERS L, KENNY J, GOLDSTEIN R, GUREWICH V, GRINSPOON L. Blood coagulation in pregnancy: proconvertin and prothrombin, and the hypercoagulable state. N Engl J Med. 1956 Feb 23; 254(8):358-63. PMID: 13288790.
    Citations: 8     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Gurewich's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (505)
Explore
_
Co-Authors (5)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.